Outcomes and Safety Profile of Repeated Progressive Site‐Directed Therapy for Patients With Oligometastatic Castration‐Resistant Prostate Cancer

Documenti analoghi

• Editorial Comment on “Outcomes and Safety Profile of Repeated Progressive Site‐Directed Therapy for Patients With Oligometastatic Castration‐Resistant Prostate Cancer”
  di: Rihito Aizawa, et al.
  Pubblicazione: (2025)
• Indirect Comparison of PROpel and TALAPRO ‐2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration‐Resistant Prostate Cancer
  di: Yosuke Yasuda, et al.
  Pubblicazione: (2025)
• Is Docetaxel Essential for Darolutamide‐Based Metastatic Hormone‐Sensitive Prostate Cancer Therapy?
  di: Wei Chen, et al.
  Pubblicazione: (2025)
• Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study
  di: Yosuke Yasuda, et al.
  Pubblicazione: (2025)
• Editorial Comment on Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR ‐ TKIs in Real‐World Patients With Advanced Renal Cell Carcinoma
  di: Hiroshi Fukushima, et al.
  Pubblicazione: (2026)